Donald Trump promises (again) to slash drug prices substantially; 'and it’s going to be beautiful’
Near the beginning of President Donald Trump’s administration, the chief executive of the country made waves in biopharma with his repeated insistence that he would roll out new initiatives that would slash the price of drugs.
Nothing much came out of that, except for the FDA’s move to ramp up approvals for new generics, which has no impact on the price of branded drugs still equipped with patent protection, which draw the most heat from reform advocates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
